Celltrion (068270)

[Business Overview] Celltrion operates as a global healthcare company, with its core business in the development and manufacturing of biosimilars (generic biopharmaceuticals). It also encompasses the development and manufacturing of novel antibody drugs and chemical drugs, as well as CDMO (Contract Development and Manufacturing Organization) services. Its key products include biosimilars such as the autoimmune disease treatments 'Remsima' and 'Yuflyma', and the oncology drugs 'Truxima', 'Herzuma', and 'Vegzelma', as well as chemical drugs like the HIV treatment 'Temixys' and the Alzheimer's treatment 'Donerion Patch'. By 2025, the proportion of biosimilars, CDMO, and novel drug development is projected to expand to 7:2:1, with the revenue contribution from high-margin new biopharmaceuticals specifically exceeding 54%. Celltrion supplies pharmaceuticals to over 100 countries worldwide and has established a direct sales network. It has secured a leading position in the global biosimilar market, with the Remsima product family recording a combined market share of 70% in the European market. [Core Competencies] Celltrion has established itself as a leader in the global biosimilar market by successfully developing 'Remsima', the world's first antibody biosimilar. Its strong competitive advantages include large-scale in-house production facilities with a capacity of 250,000L, diversification of production bases through the acquisition of a manufacturing facility in Branchburg, USA, and a global direct sales and distribution network. Furthermore, it possesses leading R&D investment and technological capabilities for the development of antibody-based novel drugs, such as Antibody-Drug Conjugates (ADCs), bispecific antibodies, and microbiomes, as well as for expanding its next-generation biosimilar pipeline. [Performance Analysis] Celltrion's revenue slightly decreased by 4.7% year-over-year to KRW 2.1764 trillion in 2023. However, it grew by 63.4% to KRW 3.5573 trillion in 2024, and further increased by 17.0% year-over-year to KRW 4.1625 trillion in 2025, achieving its highest-ever revenue. Operating income decreased by 24.5% year-over-year to KRW 492.0 billion in 2024. However, it surged by 137.5% year-over-year to KRW 1.1685 trillion in 2025, surpassing KRW 1 trillion for the first time in its history. The operating profit margin significantly improved from 13.8% in 2024 to 28.1% in 2025. This improvement is attributed to the increased revenue contribution from high-margin new products and an improved cost of goods sold (COGS) ratio due to merger synergies. [Financial Health] Celltrion's ROE declined from 12.69% in 2022 to 2.38% in 2024 but showed an improving trend to 5.94% in 2025. The debt-to-equity ratio decreased from 37.84% in 2022 to 16.53% in 2023, then slightly increased to 28.71% in 2025, but still maintains a stable level. The current ratio showed a gradual decreasing trend from 226.40% in 2022 to 139.32% in 2025. However, as it remains above 100%, its short-term debt repayment capability is assessed as sound. [Outlook] Celltrion is expanding its business areas in line with the continuous growth of the biosimilar market and the trends in next-generation therapeutic technologies. The company aims to expand its biosimilar product portfolio to 41 by 2038 and focus on developing antibody-based novel drugs, such as Antibody-Drug Conjugates (ADCs) and multi-specific antibodies, with the goal of becoming a global big pharma company. Furthermore, it plans to strengthen its production capabilities through the acquisition of a US manufacturing facility, expand its CDMO business, and increase the revenue contribution from high-margin new products to approximately 70% by 2026, thereby pursuing sustained growth.